Skip to content
Biodatica
Start free

Pliant Therapeutics, Inc.

New Haven, Connecticut

OncologyPhase IIListed · PLRX

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase I trial registered: A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

3mo agoTrial registeredApr 20, 2026Source filing (opens the source filing in a new tab)

Momentum

77no change

Momentum 77 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE2 registered

    Nov 16, 2023

    Idiopathic Pulmonary Fibrosis · TERMINATED · sponsor: Pliant Therapeutics, Inc. · Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

    ClinicalTrials.gov · NCT06097260 (opens the source filing in a new tab)

  2. Trial

    PHASE1 registered

    Aug 30, 2023

    Advanced or Metastatic Solid Tumor · RECRUITING · sponsor: Pliant Therapeutics, Inc. · A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

    ClinicalTrials.gov · NCT06270706 (opens the source filing in a new tab)

  3. Trial

    PHASE2 registered

    Jul 27, 2020

    Primary Sclerosing Cholangitis · COMPLETED · sponsor: Pliant Therapeutics, Inc. · Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)

    ClinicalTrials.gov · NCT04480840 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources